Research Article| Volume 196, P64-68, January 2016

Impact of body mass index on treatment efficacy of mirabegron for overactive bladder in females

Published:November 24, 2015DOI:



      Conclusive data comparing treatment efficacy of OAB pharmacotherapy in normal weight versus obese patients are not available. Obesity represents a risk factor for OAB/LUTS. We hypothesized that the effect of treatment with mirabegron might be diminished in obese patients.

      Study design

      One hundred sixty nine women were prescribed mirabegron, 50 mg/day. Subjective and objective parameters were compared prior to and following three months of treatment. The study population was stratified into three groups according to a patients’ BMI (A-normal weight, B-overweight, C-obese). We compared the change in parameters before and after treatment within each group. Subsequently the differences between groups were correlated. The same analysis was performed separately in patients who failed anticholinergic therapy (n = 85). A paired t-test was used to compare the parameters before and after the procedure within groups, and a two-sample t-test was applied to conduct a comparison between groups. A p value of <0.05 was considered statistically significant.


      Significant improvement (p < 0.001) within all groups was observed in all parameters, with an exception in the number of severe urgency episodes per 24 h (p = 0.291) in Group B. We did not observe any statistically significant difference between groups A, B and C. The same trend has been observed in subgroup of patients, who did not respond previous antimuscarinic treatment.


      This study provides evidence in support of previously documented data indicating good efficacy of mirabegron in the treatment of OAB. The data obtained do not confirm our hypothesis that the body weight influences the treatment outcome of mirabegron.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


        • Abrams P.
        • Artibani W.
        • Cardozo L.
        • Dmochowski R.
        • van Kerrebroeck P.
        • Sand P.
        Reviewing the ICS 2002 terminology report: the ongoing debate.
        Neurourol Urodyn. 2009; 28: 287
        • Coyne K.S.
        • Sexton C.C.
        • Irwin D.E.
        • Kopp Z.S.
        • Kelleher C.J.
        • Milsom I.
        The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study.
        BJU Int. 2008; 101: 1388-1395
        • Irwin D.E.
        • Milsom I.
        • Hunskaar S.
        • Reilly K.
        • Kopp Z.
        • Herschorn S.
        Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.
        Eur Urol. 2006; 50: 1306-1314
        • Chapple C.R.
        • Khullar V.
        • Gabriel Z.
        • Muston D.
        • Bitoun C.E.
        • Weinstein D.
        The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis.
        Eur Urol. 2008; 54: 543-562
        • Nitti V.W.
        • Auerbach S.
        • Martin N.
        • Calhoun A.
        • Lee M.
        • Herschorn S.
        Results of a randomized phase III trial of mirabegron in patients with overactive bladder.
        J Urol. 2013; 189: 1388-1395
        • Teleman P.M.
        • Lidfeldt J.
        • Nerbrand C.
        • Samsioe G.
        • Mattiasson A.
        WHILA study group. Overactive bladder: prevalence, risk factors and relation to stress incontinence in middle-aged women.
        BJOG. 2004; 111: 600-604
        • Subak L.L.
        • Whitcomb E.
        • Shen H.
        • Saxton J.
        • Vittinghoff E.
        • Brown J.S.
        Weight loss: a novel and effective treatment for urinary incontinence.
        J Urol. 2005; 174: 190-195
        • Cartwright R1
        • Panayi D.
        • Cardozo L.
        • Khullar V.
        Reliability and normal ranges for the Patient's Perception of Intensity of Urgency Scale in asymptomatic women.
        BJU Int. 2010; 105: 832-836
        • Coyne K.S.
        • Thompson C.L.
        • Lai J.S.
        • Sexton C.C.
        An overactive bladder symptom and health-related quality of life short-form: validation of the OAB-q SF.
        Neurourol Urodyn. 2015; 34: 255-263
        • Drutz H.P.
        Overactive bladder: the importance of tailoring treatment to the individual patient.
        J Multidiscip Health. 2011; 4: 233-237
        • MacDiarmid S.A.
        Maximizing anticholinergic therapy for overactive bladder: has the ceiling been reached?.
        BJU Int. 2007; 99: 8-12
        • Chapple C.R.
        • Dvorak V.
        • Radziszewski P.
        • et al.
        A phase II dose-ranging study of mirabegronin patients with overactive bladder.
        Int Urogynecol J. 2013; 24: 1447-1458
        • Nitti V.W.
        • Khullar V.
        • van Kerrebroeck P.
        • et al.
        Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double blind, placebo controlled, phase III studies.
        Int J Clin Pract. 2013; 67: 619-632
        • Krauwinkel W.
        • van Dijk J.
        • Schaddelee M.
        • et al.
        Pharmacokinetic properties of mirabegron, a β3-adrenoreceptor agonist: results from two phase I, randomized, multiple dose studies in healthy young and elderly men and women.
        Clin Ther. 2012; 34: 2144-2160
        • Matsukawa Y.
        • Takai S.
        • Funahashi Y.
        • Yamamoto T.
        • Gotoh M.
        Urodynamic evaluation of the efficacy of mirabegron on storage and voiding functions in women with overactive bladder.
        Urology. 2015; 85: 786-790
        • Serati M.
        • Braga A.
        • Siesto G.
        • et al.
        Risk factors for the failure of antimuscarinictreatment with solifenacin in women with overactive bladder.
        Urology. 2013; 82: 1044-1048
        • Chapple C.R.
        • Kaplan S.A.
        • Mitcheson D.
        • et al.
        Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year.
        Int J Urol. 2014; 21: 960-967